[ALLIANZ] QoQ Annualized Quarter Result on 30-Sep-2019 [#3]

Stock
[ALLIANZ] ALLIANZ MALAYSIA BHD
Announcement Date
27-Nov-2019
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2019
Quarter
30-Sep-2019 [#3]
Profit Trend
QoQ- 10.63%
YoY- 29.75%
Quarter Report
Latest QR
Upcoming QR
ALLIANZ's Result
ALLIANZ's Financial Summary
View:
Show?
Annualized Quarter Result
30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 CAGR
Revenue 5,777,622 5,938,824 5,534,374 5,505,204 5,420,620 5,377,180 5,181,929 7.53%
PBT 681,090 367,788 692,144 671,981 657,910 604,960 518,984 19.88%
Tax -186,626 -49,788 -199,666 -192,786 -224,742 -209,292 -141,963 20.02%
NP 494,464 318,000 492,478 479,194 433,168 395,668 377,021 19.83%
-
NP to SH 494,464 318,000 492,478 479,194 433,168 395,668 377,021 19.83%
-
Tax Rate 27.40% 13.54% 28.85% 28.69% 34.16% 34.60% 27.35% -
Total Cost 5,283,158 5,620,824 5,041,896 5,026,009 4,987,452 4,981,512 4,804,908 6.53%
-
Net Worth 3,965,873 3,739,429 3,669,934 3,788,212 3,628,616 3,485,076 3,322,561 12.53%
Dividend
30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 CAGR
Div - - 114,851 - - - 69,838 -
Div Payout % - - 23.32% - - - 18.52% -
Equity
30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 CAGR
Net Worth 3,965,873 3,739,429 3,669,934 3,788,212 3,628,616 3,485,076 3,322,561 12.53%
NOSH 176,888 176,888 176,887 176,767 176,767 176,767 176,688 0.07%
Ratio Analysis
30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 CAGR
NP Margin 8.56% 5.35% 8.90% 8.70% 7.99% 7.36% 7.28% -
ROE 12.47% 8.50% 13.42% 12.65% 11.94% 11.35% 11.35% -
Per Share
30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 CAGR
RPS 3,266.22 3,357.38 3,132.18 3,115.76 3,066.88 3,042.63 2,967.95 6.59%
EPS 279.54 179.76 203.87 271.11 245.08 223.88 167.90 40.51%
DPS 0.00 0.00 65.00 0.00 0.00 0.00 40.00 -
NAPS 22.42 21.14 20.77 21.44 20.53 19.72 19.03 11.55%
Adjusted Per Share Value based on latest NOSH - 176,767
30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 CAGR
RPS 3,244.33 3,334.85 3,107.74 3,091.36 3,043.86 3,019.47 2,909.83 7.53%
EPS 277.66 178.57 276.54 269.08 243.24 222.18 211.71 19.83%
DPS 0.00 0.00 64.49 0.00 0.00 0.00 39.22 -
NAPS 22.2697 20.9981 20.6079 21.2721 20.3759 19.5699 18.6573 12.53%
Price Multiplier on Financial Quarter End Date
30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 CAGR
Date 30/06/20 31/03/20 31/12/19 30/09/19 28/06/19 29/03/19 31/12/18 -
Price 14.10 12.48 16.28 13.84 14.00 14.50 13.00 -
P/RPS 0.43 0.37 0.52 0.44 0.46 0.48 0.44 -1.52%
P/EPS 5.04 6.94 5.84 5.10 5.71 6.48 6.02 -11.18%
EY 19.82 14.40 17.12 19.60 17.51 15.44 16.61 12.51%
DY 0.00 0.00 3.99 0.00 0.00 0.00 3.08 -
P/NAPS 0.63 0.59 0.78 0.65 0.68 0.74 0.68 -4.96%
Price Multiplier on Announcement Date
30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 31/03/19 31/12/18 CAGR
Date 27/08/20 16/06/20 27/02/20 27/11/19 22/08/19 23/05/19 21/02/19 -
Price 13.48 14.30 15.70 14.00 13.80 13.18 14.00 -
P/RPS 0.41 0.43 0.50 0.45 0.45 0.43 0.47 -8.71%
P/EPS 4.82 7.95 5.63 5.16 5.63 5.89 6.48 -17.92%
EY 20.74 12.57 17.75 19.37 17.76 16.99 15.42 21.86%
DY 0.00 0.00 4.14 0.00 0.00 0.00 2.86 -
P/NAPS 0.60 0.68 0.76 0.65 0.67 0.67 0.74 -13.05%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment